We are live on
!
Find out more
BE
Bonness Enterprises Portfolio holdings
AUM
$310M
1-Year Est. Return
24.22%
This Fund
S&P 500
This Quarter
Est. Return
+2.33%
1 Year Est. Return
+24.22%
3 Year Est. Return
+94.56%
5 Year Est. Return
+137.52%
10 Year Est. Return
+441.57%
AUM
$217M
AUM Growth
+$815K
(+0.38%)
Cap. Flow
-$2M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
65.4%
Holding
41
New
–
Increased
4
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$280K |
| 2 |
Intel
INTC
|
+$273K |
| 3 |
Philips
PHG
|
+$76K |
| 4 |
IBM
IBM
|
+$13K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nucor
NUE
|
+$2.38M |
| 2 |
Viatris
VTRS
|
+$144K |
| 3 |
AT&T
T
|
+$66.1K |
| 4 |
CAJ
Canon, Inc.
CAJ
|
+$24K |
| 5 |
GE Aerospace
GE
|
+$23.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.4% |
| 2 | Healthcare | 29.67% |
| 3 | Technology | 23.69% |
| 4 | Industrials | 3.97% |
| 5 | Consumer Staples | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Progressive
PGR
$122B
| $65.4M | 30.09% |
573,653
| – | – |
|
2
Stryker
SYK
$130B
| $18.3M | 8.41% |
68,366
| – | – |
|
3
Microsoft
MSFT
$3.63T
| $14.2M | 6.55% |
46,200
| – | – |
|
4
Apple
AAPL
$4.51T
| $9.59M | 4.41% |
54,940
| – | – |
|
5
Johnson & Johnson
JNJ
$609B
| $6.92M | 3.18% |
39,038
| – | – |
|
6
Thermo Fisher Scientific
TMO
$213B
| $6.73M | 3.1% |
11,400
| – | – |
|
7
AbbVie
ABBV
$434B
| $5.98M | 2.75% |
36,900
| – | – |
|
8
Merck
MRK
$314B
| $5.7M | 2.62% |
69,500
| – | – |
|
|
9
Intel
INTC
$456B
| $4.68M | 2.15% |
94,450
+5,500
| +6% | +$273K |
|
10
Cisco
CSCO
$454B
| $4.61M | 2.12% |
82,700
| – | – |
|
|
11
Pfizer
PFE
$142B
| $4.48M | 2.06% |
86,608
+5,400
| +7% | +$280K |
|
|
MRSH
12
Marsh
MRSH
$91.5B
| $4.38M | 2.02% |
25,700
| – | – |
|
13
Emerson Electric
EMR
$85.3B
| $4.26M | 1.96% |
43,500
| – | – |
|
14
Applied Materials
AMAT
$408B
| $4.13M | 1.9% |
31,300
| – | – |
|
|
15
Nucor
NUE
$58.9B
| $4.08M | 1.88% |
27,435
-19,415
| -41% | -$2.38M |
|
16
Bristol-Myers Squibb
BMY
$132B
| $4M | 1.84% |
54,800
| – | – |
|
17
Abbott
ABT
$185B
| $3.87M | 1.78% |
32,700
| – | – |
|
|
18
IBM
IBM
$214B
| $3.84M | 1.77% |
29,564
+100
| +0.3% | +$13K |
|
19
Unilever
UL
$137B
| $3.46M | 1.59% |
67,591
| – | – |
|
20
United Parcel Service
UPS
$90.5B
| $3.21M | 1.48% |
14,950
| – | – |
|
21
GSK
GSK
$102B
| $2.88M | 1.33% |
52,960
| – | – |
|
22
John Wiley & Sons Class A
WLY
$2.67B
| $2.57M | 1.18% |
48,400
| – | – |
|
23
Procter & Gamble
PG
$337B
| $2.51M | 1.15% |
16,400
| – | – |
|
24
Verizon
VZ
$198B
| $2.42M | 1.12% |
47,587
| – | – |
|
25
Agilent Technologies
A
$39.2B
| $2.37M | 1.09% |
17,900
| – | – |
|
Similar funds
IPW
TL
RGC
IR
TWM
PH
CCG
FI
Bonness Enterprises's Q1 2022 Portfolio in Review
As of Q1 2022, Bonness Enterprises held 41 positions worth $217M, up 0.38% from $217M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 2.4%. Bonness Enterprises opened no new positions and exited 1, leaving the 41-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 31% a quarter earlier, followed by Healthcare and Technology.
- Bonness Enterprises added most to Pfizer in Q1 2022, an estimated $280K increase.
- Bonness Enterprises's biggest Q1 2022 reduction was Nucor, cutting an estimated $2.38M.
- Bonness Enterprises fully exited Viatris in Q1 2022, selling an estimated $144K.
- Bonness Enterprises's ten largest holdings make up 65% of its $217M portfolio in Q1 2022.
- Bonness Enterprises opened 0 new positions and closed 1 in Q1 2022.
- Bonness Enterprises's portfolio value rose 0.38% quarter-over-quarter to $217M.
Based on Bonness Enterprises's 13F filing for Q1 2022, filed 8 Apr 2022.